Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36714 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction ...

Washington, DC 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Mark One) ⌧ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO. 001-36714 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 46-2956775 (State or other jurisd ...

Jaguar Health, Inc. (NASDAQ:JAGX) Q3 2020 Earnings Conference Call November 16, 2020 8:30 AM ET Company Participants Lisa Conte - President & Chief Executive Officer Carol Lizak - Senior Vice President, Finance & Chief Accounting Officer Ian Wendt - Vice President, Commercial Strategy Pravin Chaturvedi - Chief Scientific Officer Michael Guy - Vice President, Preclinical & Nonclinical Studies Steven King - Chief Sustainable Supply Ethnobotanical Research and IP Officer Peter Hodge - Senior Director of Invest ...

WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) Table of Contents ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) (415) 371-8300 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) (Registrant's telephone number, including area code) Delaware 46-2956775 200 Pine Street, Suite 400 For the quarterly per ...

WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36714 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURIT ...

Jaguar Health, Inc. (NASDAQ:JAGX) Q1 2020 Earnings Conference Call May 15, 2020 8:30 AM ET Company Participants Lisa Conte – Founder and Chief Executive Officer Carol Lizak – Senior Vice President-Finance and Chief Accounting Officer Ian Wendt – Vice President-Commercial Strategy Conference Call Participants Operator Welcome to the Jaguar Health Investor Conference Call. Before I turn the call over to management, I’d like to remind you that management may make forward-looking statements relating to such mat ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q For the transition period from to Commission file number 001-36714 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) Delaware 46-2956775 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ...

Jaguar Health, Inc. (NASDAQ:JAGX) Q4 2019 Results Earnings Conference Call April 6, 2020 8:30 AM ET Company Participants Lisa Conte - Founder, President and CEO Carol Lizak - Senior VP of Finance and Chief Accounting Officer Ian Wendt - Vice President, Commercial Strategy Steven King - Executive Vice President, Sustainable Supply, Ethnobotanical Research and Intellectual Property Pravin Chaturvedi - CSO Conference Call Participants Operator Good day and welcome to the Jaguar Health Investor Call. Today's co ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO. 001-36714 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 46‑2956775 (State or other jurisd ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (Exact name of registrant as specified in its charter) FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36714 JAGUAR HEALTH, INC. (State or other jurisdict ...